Imperial College LondonStem cells could offer hope for patients with lung damage from COPD and asthmaImperial College LondonEarly stage trials have shown promise for a cell-based therapy for treating lung tissue damaged by respiratory diseases. In a co… Continue reading
Imperial College LondonStem cells could offer hope for patients with lung damage from COPD and asthmaImperial College LondonEarly stage trials have shown promise for a cell-based therapy for treating lung tissue damaged by respiratory diseases. In a co… Continue reading
Technology NetworksUmbilical Cord-Derived Stem Cells Could Help Those with Heart FailureTechnology NetworksUmbilical cord-derived stem cells could be the answer for patients with heart failure (HF). A study published yesterday in Circulation Research, … Continue reading
Heart failure could be treated using umbilical cord stem cellsMedical News TodayThe authors of the new study note that previous research has already looked into the potential of stem cells derived from bone marrow for treating heart failure, but they s… Continue reading
PR Web (press release) |
TeselaGen’s Mike Fero to Speak at SynBioBeta SF 2017
PR Web (press release) TeselaGen founder and CEO Mike Fero has been selected to speak at SynBioBeta SF 2017, the annual conference bringing together entrepreneurs, investors, and practitioners to drive the synthetic biology industry forward. Other speakers at the industry’s … |
Proactive Investors Australia |
Cynata Therapeutics wins US patent for stem cell technology
Proactive Investors Australia Cynata’s new patent covers the proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells at scale. The Cymerus process includes donor screening and testing, the induced pluripotent stem cell (iPSC … |
Press Telegraph |
Editas Medicine Receives EMA’s Orphan Medicinal Product …
Nasdaq CAMBRIDGE, Mass., Sept. 26, 2017– Editas Medicine, Inc., a leading genome editing company, today announced the European Medicines Agency granted. Editas Medicine, Inc. (NASDAQ:EDIT) Moving Today – Down $0.85First News 24 |